{"schema":"sb.node.v1","id":"sb:e/85b8fa41ea2140de23cfa108","kind":"entity","label":{"text":"inds","locale":"en"},"identity":{"anchor":"label:en:inds","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T23:27:45.667496+00:00","snapshot":"deploy 4af43c9edf2bfd81ea08d6576c6a9da23330cce3"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":35,"separatePublishers":3,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.257,"named":9,"of":35,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only","blind":["only 26% of the 35 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-12","to":"2026-10-09","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.457: about 54% of mentions carry no typed assertion"]}},"dimensions":{"domains":["pharma-regulatory","biotech_pharma"],"activeDays":25,"assertions":{"regulatory-approval":14,"launch-release":2}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":9,"byKind":{"observation":9},"items":[{"id":"sb:o/1b989cd525c85d12bce5a6b0","kind":"observation","label":"FDA Drug News · 2026-07-08 · Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations","url":"http://www.fda.gov/drugs/guidances-drugs/guidance-recap-podcast-assessing-effects-food-drugs-inds-and-ndas-clinical-pharmacology"},{"id":"sb:o/8e1a69cc8ae3273a90068ee3","kind":"observation","label":"FDA Drug News · 2026-05-20 · Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations","url":"http://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-effects-food-drugs-inds-and-ndas-clinical-pharmacology-considerations"},{"id":"sb:o/0365ad7d15c6543e43dd1608","kind":"observation","label":"FDA · 2026-10-09 · Phase 1 IND Frequently Asked Questions","url":"http://www.fda.gov/industry/phase-1-investigational-new-drug-ind-navigator/phase-1-ind-frequently-asked-questions"},{"id":"sb:o/c097471d31185fd20f80726d","kind":"observation","label":"The Clinical Trial Vanguard · 2026-10-03 · DHHS Releases 2026 Unified Agenda With Five Clinical Research Rule Changes","url":"https://www.clinicaltrialvanguard.com/news/dhhs-releases-2026-unified-agenda-with-five-clinical-research-rule-changes/"},{"id":"sb:o/95a2665c677eeb377c0d0e74","kind":"observation","label":"FDA · 2026-09-17 · Investigational New Drug Application (IND)","url":"http://www.fda.gov/drugs/types-applications/investigational-new-drug-application-ind"},{"id":"sb:o/11d010bdf0581f52b91b437f","kind":"observation","label":"FDA · 2026-09-04 · Phase 1 IND Chemistry, Manufacturing, and Controls Flexibilities","url":"http://www.fda.gov/industry/phase-1-investigational-new-drug-ind-navigator/phase-1-ind-chemistry-manufacturing-and-controls-flexibilities"},{"id":"sb:o/f1ada45e39934a1cfbfd15e6","kind":"observation","label":"FDA Drug News · 2026-06-22 · Phase 1 IND Federal Regulations","url":"http://www.fda.gov/industry/phase-1-investigational-new-drug-ind-navigator/phase-1-ind-federal-regulations"},{"id":"sb:o/a2c41f080ff4a819912aeb78","kind":"observation","label":"FDA Drug News · 2026-06-18 · Investigational New Drug (IND) Application","url":"http://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application"},{"id":"sb:o/eb346dcbcb83b01d2d372457","kind":"observation","label":"FDA Drug News · 2026-04-12 · Bioanalytical Method Validation for Biomarkers","url":"http://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-biomarkers"}],"cursor":null,"order":"newest first; we keep the 9 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":9,"byKind":{"co-mentioned":9},"items":[{"kind":"relation","label":"co-mentioned with fda (30 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e31028c04ea5cce56dabb32d"},{"kind":"relation","label":"co-mentioned with drug administration (16 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f60511d58821b09de14442c7"},{"kind":"relation","label":"co-mentioned with investigational new drug (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/09e3701874a52c6dbfe2510c"},{"kind":"relation","label":"co-mentioned with adverse events (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f48de21bbe2b1701e25dfbfa"},{"kind":"relation","label":"co-mentioned with cder (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d5dbe544f3c456d9b1b7960c"},{"kind":"relation","label":"co-mentioned with medwatch (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2c116303d0290bad903e329b"},{"kind":"relation","label":"co-mentioned with reporting system (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7b5f1577336d1f1a8ff5cfca"},{"kind":"relation","label":"co-mentioned with clinical trials (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d28205f5866216428f38a467"},{"kind":"relation","label":"co-mentioned with oncology center (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/937dd10d280c6d0ebba15a2d"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/85b8fa41ea2140de23cfa108","mcp":"traverse {\"id\":\"sb:e/85b8fa41ea2140de23cfa108\"}","page":"/entity/inds/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/85b8fa41ea2140de23cfa108\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/85b8fa41ea2140de23cfa108\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/85b8fa41ea2140de23cfa108\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/85b8fa41ea2140de23cfa108\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}